Intercure

InterCure will effect a 1:5 reverse split, effective at the market open on August 24, 2026, to regain Nasdaq’s $1.00 minimum bid price. The authorized share capital will be reduced to 20,000,000 common shares and outstanding shares will fall to approximately 11,845,711; fractional shares will be rounded down. The company expects to receive a Nasdaq delisting notice and intends to appeal; during the appeal InterCure expects the shares to remain tradable. Equity-based compensation and outstanding options will be adjusted proportionally; holders of physical certificates will receive instructions from the transfer agent. » More on de.investing.com

InterCure was censured because its common stock closed below $1.00 for 30 consecutive trading days; the share price is currently $0.83. Nasdaq has set a 180-calendar-day deadline until August 24, 2026, during which the closing price must be at or above $1.00 for at least ten consecutive trading days, otherwise a possible extension or delisting could be considered. InterCure is examining a reverse split to regain compliance and reports a market capitalization of $46.89 million and most recently $72.18 million in revenue. » More on de.investing.com

Intercure announces the annual shareholders' meeting for December 30, 2025 at 16:00 Israel time in the offices of Amit, Pollak, Matalon & Co. in Ramat Hachayal, Tel Aviv. The company has published a Notice and Proxy Statement explaining voting procedures and options for in-person voting or representation by proxy. The SEC filing does not list any specific agenda items. Intercure is registered in Israel and operates in the pharmaceutical preparations sector. » More on de.investing.com